Developer docs
API playgroundTry for free, no card

Search company profiles

CogNano

Full company profile

uuid000f1zs

Namestring
CogNano
Legal namestring
株式会社COGNANO
Websiteurl
cognano.co.jp
Company typeenum
Private
Founded yearint
2014
Descriptiontext

CogNano (株式会社COGNANO) is a Kyoto-based biotechnology company founded in October 2014 that has built the world's largest proprietary library of alpaca-derived VHH (Variable domain of Heavy chain of Heavy chain antibody) sequences, accumulating 300 million antibody gene reads and 30 million labeled antibody clones across 50 antigen types over 15 years. The company's core technology, IBMET (Inverse Biomarker Exploring Technology), combines next-generation sequencing, statistical analysis, and large language models in a reverse biomarker discovery approach — using immune-system-derived antibody information to discover disease-specific structural targets rather than starting from known targets. This forms the basis of its 'Structure-Omics' positioning, which targets disease areas where conventional genomics, proteomics, and AlphaFold-style tools have failed, including TNBC, pancreatic cancer, bile duct cancer, and glioblastoma.

CogNano's revenue model mixes multiple mechanisms: VHH antibody samples are provided free to academic researchers under a Material Transfer Agreement; labeled datasets (AVIDa-hIL6, AVIDa-SARS-CoV-2, AVIDa-hTNFa, VHHCorpus-2M) are publicly available on Hugging Face under CC BY-NC 4.0 with commercial licensing by direct inquiry; biomarker discovery services are negotiated bilaterally with pharma/biotech clients; discovered structural targets are licensed as the basis for antibody drugs, ADCs, CAR-T, and cell therapies; and the company intends to spin out disease-specific 'daughter ventures' taking equity and royalties. Customers span pharmaceutical and biotech companies (primary), AI/ML researchers (academic), and diagnostic and research reagent companies. The company has established a US subsidiary, COGNANOUS, Inc., in Somerville, MA, maintains research collaborations with Kyoto University, Osaka University, Tokyo University, and AMED, and is the sole Japanese member of the OpenFold consortium and a founding partner of the SEPIQ non-profit VHH benchmarking consortium. Management is led by physician-scientist CEO Akihiro Imura (Kyoto University MD/PhD) and CFO Taeko Imura, with Ryosuke Matsumoto appointed CTO from Sakura Internet in 2022 to drive the bio-IT convergence strategy.

Short descriptiontext

CogNano is a Kyoto-based biotech that uses proprietary alpaca VHH antibody data and AI/ML (IBMET) to discover disease-specific structural biomarkers for pharmaceutical and diagnostic partners, targeting cancers with no known biomarkers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersKyoto, Japan
HQ citystring
Kyoto
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
VHH antibody discovery, biomarker identification services, AI-driven drug discovery, structural target discovery, nanobody library data
Industry4 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Biotechnology / Antibody Drug Discovery
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Research Use VHH Antibody Sample Provision
TypeProfessional Services
Description

COGNANO provides high-quality VHH antibody samples to research institutions and companies for evaluation under a Material Transfer Agreement (MTA). Sample evaluation can lead to joint research or license agreements.

cognano.co.jp
2Data Licensing
TypeData Monetisation
Description

Licensing of proprietary labeled VHH antibody datasets (AVIDa-hIL6, AVIDa-SARS-CoV-2, VHHCorpus-2M) to AI researchers, pharmaceutical companies, and biotech firms. Datasets are publicly posted on Hugging Face under CC BY-NC 4.0; commercial licensing is handled via direct inquiry.

cognano.co.jp
3Biomarker Discovery Services
TypeProfessional Services
Description

Fee-for-service biomarker discovery engagements using IBMET technology and the VHH antibody platform to identify disease-specific structural biomarkers for pharmaceutical and diagnostic company clients.

cognano.co.jp
4Drug Target Licensing
TypeLicensing Royalties
Description

Licensing of discovered disease-specific structural targets (e.g., TNBC biomarkers, pancreatic cancer markers) to pharmaceutical companies for drug development. Targets serve as the basis for antibody drugs, ADCs, CAR-T therapies, and cell therapy targets.

cognano.co.jp
5Daughter Venture Equity / Royalties
TypeLicensing Royalties
Description

COGNANO plans to spin out disease-specific ventures ('daughter ventures') per disease area and region, taking equity stakes and royalty income. Each daughter venture would involve academic partners, hospitals, investors, CROs, and pharma companies.

cognano.co.jp
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Research evaluation sample — free for qualified non-commercial research
ModelFreemiumBilling cadenceOne time
Notes

VHH antibody samples provided at no cost for non-profit research evaluation. Recipients must agree to the VHH Antibody Provision and Analysis Agreement. Commercial and clinical use is prohibited. Commercial licensing is handled separately via direct inquiry (avid@cognano.co.jp).

cognano.co.jp
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

CogNano designs and produces VHH (single-domain) antibodies derived from its proprietary alpaca colonies and combines next-generation sequencing data with machine learning and large language models to discover disease-specific structural biomarkers and drug targets for pharmaceutical and diagnostic partners. The company licenses labeled VHH antigen-antibody datasets, provides research-use antibody samples under Material Transfer Agreements, and offers fee-for-service biomarker discovery engagements alongside drug target licensing to pharma and biotech clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Discovered TNBC (Triple-Negative Breast Cancer) structural biomarkers — a disease with no previously known biomarkers — and published findings in academic paper; research has advanced to mouse experiments.
+3 more records
Product overview1 text field

COGNANO is a biotech company that develops VHH (alpaca-derived heavy-chain) antibody big data and applies AI/machine learning to discover disease-specific structural biomarkers for drug discovery. Its portfolio consists of three layers: (1) proprietary VHH antibody datasets — AVIDa-hIL6 (573K pairs, IL-6), AVIDa-SARS-CoV-2 (77K pairs, 12 variants), AVIDa-hTNFa, and VHHCorpus-2M (2M+ sequences) — available on HuggingFace under open licenses; (2) IBMET (Inverse Biomarker Exploring Technology), the core AI-powered biomarker discovery platform that uses statistical labeling and LLM-based analysis to identify disease-specific molecular structures from the antibody data; and (3) research evaluation VHH antibody samples provided to partners under MTA. COGNANO's Structure-Omics concept integrates VHH antibody big data, NGS sequencing, and computational analysis to discover novel drug targets that traditional genomics/proteomics cannot find.

Product and service1 record
1VHH Antibody Library
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1SEPIQ (非営利コンソーシアム)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

COGNANO provides its massive labeled VHH antibody datasets to the non-profit SEPIQ consortium, which organizes the SEPIQ VHH Epitope Prediction Challenge 2026. SEPIQ aims to establish global benchmarks for AI-driven epitope prediction. Co-hosted with CAPRI and OpenFold.

cognano.co.jp
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-04-17
Description

COGNANO participates in OpenFold, a non-profit consortium promoting AI-driven computational structural biology. Japan-based only company participating in this global consortium alongside leading biotech companies and academic institutions.

3Sakura Internet (さくらインターネット株式会社)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-30
Description

Joint AI drug discovery research with Sakura Internet Research Institute. Co-authored NeurIPS 2024 paper on AVIDa-SARS-CoV-2 VHH dataset and antibody language models. Sakura Internet built AI models for antigen-antibody interaction prediction using COGNANO's labeled datasets. Long-term research collaboration since 2020.

cognano.co.jp
4Osaka University — Namba Laboratory (大阪大学 難波啓一特任教授)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-01
Description

Cryo-electron microscopy analysis of antigen-antibody complexes for COGNANO's VHH antibodies (including SARS-CoV-2 and TNBC projects). Structural biology expertise supporting COGNANO's biomarker validation.

cognano.co.jp
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-15
Description

Joint research on alpaca breeding efficiency improvement and alpaca VHH antibody technology development. Long-standing partnership supporting COGNANO's core alpaca colony research capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-04-01
Description

Long-standing research collaboration on SARS-CoV-2 VHH antibody development, HIV-1 antibody drug and CAR-T therapy development, and TNBC biomarker research. Kyoto University provides virus experiments and clinical expertise. COGNANO provides VHH antibody discovery platform.

7Japan Agency for Medical Research and Development (国立研究開発法人 日本医療研究開発機構 / AMED)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

COGNANO participates in AMED-funded virus and infectious disease technology development programs as a research collaborator. Projects include SARS-CoV-2 treatment antibody development and HIV-1 antibody drug development.

cognano.co.jp
8UAB (Ukraine Association of Biobank)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

COGNANO is exploring biobank partnership with UAB to access diverse patient samples for biomarker validation. UAB relocated from Kharkiv to Graz, Austria during the Russia-Ukraine war, maintaining a centralized biobank.

cognano.co.jp
9Osaka University — Inoue Laboratory (大阪大学 井上豪教授)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Science advisor and participant in AMED-BINDS program. Provides expertise in X-ray crystallography, cryo-electron microscopy, and structural biology for COGNANO's biomarker validation research.

cognano.co.jp
10Tokyo University — Wada Laboratory (東京大学 和田教授)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

COGNANO collaborates with Tokyo University researchers on SARS-CoV-2 VHH antibody development. Provides virology expertise and experimental validation capabilities.

cognano.co.jp
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

COGNANO has been receiving mentorship from CIC Cambridge since November 2022. CIC introduced COGNANO to bio/tech mentors in Boston and facilitated connections with pharmaceutical companies and investors in the US biotech ecosystem.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Recursion is a publicly-traded AI drug discovery company combining high-throughput biology, chemistry, and machine learning at scale. It is comparable to CogNano as a fellow AI-driven target and drug discovery platform, but operates at vastly larger scale with a broader pipeline and a different underlying data modality (high-throughput phenotypic screening vs. VHH antibody-based target discovery).

TypeBroad incumbent
Description

Insilico Medicine is an AI-driven drug discovery company with end-to-end capabilities from target identification through clinical development. It is comparable to CogNano as a fellow AI-discovered target company pursuing novel disease biology (longevity, fibrosis, oncology), but is far more capitalized, employs a generative chemistry–centric approach, and competes for the same pharma partnership opportunities.

TypeDirect peer
Description

AbCellera is a leading antibody discovery platform partnering with pharma to discover fully human therapeutic antibodies using single-cell screening and AI. It is the most directly comparable peer to CogNano in antibody discovery, though AbCellera focuses on human mAbs at massive scale and partnered economics (e.g., with Eli Lilly for COVID-19 antibodies) while CogNano focuses on alpaca VHHs with a data/AI-centric moat.

TypeDirect peer
Description

Adimab is a privately-held antibody discovery and engineering company offering a yeast-based platform for therapeutic antibody leads. It is directly comparable to CogNano as an antibody platform business with pharma partnership economics, but focuses on human/yeast display antibodies rather than alpaca VHHs and offers engineering rather than target discovery as its core value.

TypeDirect peer
Description

BigHat Biosciences designs next-generation antibody therapeutics using a wet lab + ML platform for antibody engineering. It is a close peer to CogNano in combining biological antibody data with AI/ML to produce better therapeutic candidates, though focused on engineering existing antibodies rather than discovering novel disease targets.

TypeEmerging player
Description

Generate Biomedicines is a Flagship Pioneering company using generative AI to design novel protein therapeutics including antibodies. It is comparable to CogNano as a generative biology company pursuing programmable biologics, but focuses on de novo protein generation rather than target discovery from VHH libraries and is far more capitalized.

7Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs is Alphabet's drug discovery company applying DeepMind's AI (AlphaFold) to pharma R&D. It is comparable to CogNano as an AI-driven drug discovery company, but operates at the hyperscaler level, focuses on structure prediction and chemistry, and competes for global pharma partnerships at a different scale.

8Antiverse
TypeEmerging player
Description

Antiverse is a UK-based startup using AI/ML to design antibody therapeutics, including a platform for novel antigen discovery. It is comparable to CogNano as an AI-driven antibody discovery peer at a similar early stage, though focused on in silico antibody design against known targets rather than alpaca-library-driven novel target discovery.

TypeDirect peer
Description

NaturalAntibody is a Poland-based antibody AI engineering service that partners with CogNano on antibody data processing workflows. It is a direct peer in the AI antibody space, offering data/AI tooling for antibody discovery and engineering with comparable scientific positioning but a service-model rather than proprietary animal-library business.

TypeEmerging player
Description

Cradle is an Amsterdam-based AI protein design company focused on generative models for therapeutic and industrial proteins. It is comparable to CogNano as a generative biology peer operating in adjacent modalities, but focuses on general protein design rather than antibody target discovery and serves different downstream customers.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CogNano

Biotechnology / Antibody Drug Discoverycognano.co.jp

CogNano is a Kyoto-based biotech that uses proprietary alpaca VHH antibody data and AI/ML (IBMET) to discover disease-specific structural biomarkers for pharmaceutical and diagnostic partners, targeting cancers with no known biomarkers.

What CogNano does

CogNano (株式会社COGNANO) is a Kyoto-based biotechnology company founded in October 2014 that has built the world's largest proprietary library of alpaca-derived VHH (Variable domain of Heavy chain of Heavy chain antibody) sequences, accumulating 300 million antibody gene reads and 30 million labeled antibody clones across 50 antigen types over 15 years. The company's core technology, IBMET (Inverse Biomarker Exploring Technology), combines next-generation sequencing, statistical analysis, and large language models in a reverse biomarker discovery approach — using immune-system-derived antibody information to discover disease-specific structural targets rather than starting from known targets. This forms the basis of its 'Structure-Omics' positioning, which targets disease areas where conventional genomics, proteomics, and AlphaFold-style tools have failed, including TNBC, pancreatic cancer, bile duct cancer, and glioblastoma.

CogNano's revenue model mixes multiple mechanisms: VHH antibody samples are provided free to academic researchers under a Material Transfer Agreement; labeled datasets (AVIDa-hIL6, AVIDa-SARS-CoV-2, AVIDa-hTNFa, VHHCorpus-2M) are publicly available on Hugging Face under CC BY-NC 4.0 with commercial licensing by direct inquiry; biomarker discovery services are negotiated bilaterally with pharma/biotech clients; discovered structural targets are licensed as the basis for antibody drugs, ADCs, CAR-T, and cell therapies; and the company intends to spin out disease-specific 'daughter ventures' taking equity and royalties. Customers span pharmaceutical and biotech companies (primary), AI/ML researchers (academic), and diagnostic and research reagent companies. The company has established a US subsidiary, COGNANOUS, Inc., in Somerville, MA, maintains research collaborations with Kyoto University, Osaka University, Tokyo University, and AMED, and is the sole Japanese member of the OpenFold consortium and a founding partner of the SEPIQ non-profit VHH benchmarking consortium. Management is led by physician-scientist CEO Akihiro Imura (Kyoto University MD/PhD) and CFO Taeko Imura, with Ryosuke Matsumoto appointed CTO from Sakura Internet in 2022 to drive the bio-IT convergence strategy.

CogNano firmographics

Firmographics
Name
CogNano
Legal name
株式会社COGNANO
Website
https://cognano.co.jp
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
CogNano is a Kyoto-based biotech that uses proprietary alpaca VHH antibody data and AI/ML (IBMET) to discover disease-specific structural biomarkers for pharmaceutical and diagnostic partners, targeting cancers with no known biomarkers.
Ownership category
akta.pro rank

CogNano industry classification

Industry
Product category
Biotechnology / Antibody Drug Discovery
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Keywords

  • VHH antibody discovery
  • Biomarker identification services
  • AI-driven drug discovery
  • Structural target discovery
  • Nanobody library data

Where CogNano is headquartered

Location

Headquarters

HQ city
Kyoto
HQ country
Japan
HQ region
Asia

Offices3 records

Markets served

CogNano business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Research Use VHH Antibody Sample Provision: COGNANO provides high-quality VHH antibody samples to research institutions and companies for evaluation under a Material Transfer Agreement (MTA). Sample evaluation can lead to joint research or license agreements.
  2. Data Licensing: Licensing of proprietary labeled VHH antibody datasets (AVIDa-hIL6, AVIDa-SARS-CoV-2, VHHCorpus-2M) to AI researchers, pharmaceutical companies, and biotech firms. Datasets are publicly posted on Hugging Face under CC BY-NC 4.0; commercial licensing is handled via direct inquiry.
  3. Biomarker Discovery Services: Fee-for-service biomarker discovery engagements using IBMET technology and the VHH antibody platform to identify disease-specific structural biomarkers for pharmaceutical and diagnostic company clients.
  4. Drug Target Licensing: Licensing of discovered disease-specific structural targets (e.g., TNBC biomarkers, pancreatic cancer markers) to pharmaceutical companies for drug development. Targets serve as the basis for antibody drugs, ADCs, CAR-T therapies, and cell therapy targets.
  5. Daughter Venture Equity / Royalties: COGNANO plans to spin out disease-specific ventures ('daughter ventures') per disease area and region, taking equity stakes and royalty income. Each daughter venture would involve academic partners, hospitals, investors, CROs, and pharma companies.

Pricing tiers

ModelBillingPrice
FreemiumOne timeResearch evaluation sample — free for qualified non-commercial research

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

CogNano product offering

Product offering

Core offering

CogNano designs and produces VHH (single-domain) antibodies derived from its proprietary alpaca colonies and combines next-generation sequencing data with machine learning and large language models to discover disease-specific structural biomarkers and drug targets for pharmaceutical and diagnostic partners. The company licenses labeled VHH antigen-antibody datasets, provides research-use antibody samples under Material Transfer Agreements, and offers fee-for-service biomarker discovery engagements alongside drug target licensing to pharma and biotech clients.

Product overview

COGNANO is a biotech company that develops VHH (alpaca-derived heavy-chain) antibody big data and applies AI/machine learning to discover disease-specific structural biomarkers for drug discovery. Its portfolio consists of three layers: (1) proprietary VHH antibody datasets — AVIDa-hIL6 (573K pairs, IL-6), AVIDa-SARS-CoV-2 (77K pairs, 12 variants), AVIDa-hTNFa, and VHHCorpus-2M (2M+ sequences) — available on HuggingFace under open licenses; (2) IBMET (Inverse Biomarker Exploring Technology), the core AI-powered biomarker discovery platform that uses statistical labeling and LLM-based analysis to identify disease-specific molecular structures from the antibody data; and (3) research evaluation VHH antibody samples provided to partners under MTA. COGNANO's Structure-Omics concept integrates VHH antibody big data, NGS sequencing, and computational analysis to discover novel drug targets that traditional genomics/proteomics cannot find.

Differentiator

Problem solved

Functional benefit

Products and services

  • VHH Antibody Library

Quantifiable outcome

  • Discovered TNBC (Triple-Negative Breast Cancer) structural biomarkers — a disease with no previously known biomarkers — and published findings in academic paper; research has advanced to mouse experiments.
  • +3 more outcomes

Companies that use CogNano

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

CogNano technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

CogNano partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

  • SEPIQ (非営利コンソーシアム)coreStrategic or Co-development Partner · 23 March 2026COGNANO provides its massive labeled VHH antibody datasets to the non-profit SEPIQ consortium, which organizes the SEPIQ VHH Epitope Prediction Challenge 2026. SEPIQ aims to establish global benchmarks for AI-driven epitope prediction. Co-hosted with CAPRI and OpenFold.
  • OpenFold ConsortiummajorStrategic or Co-development Partner · 17 April 2025COGNANO participates in OpenFold, a non-profit consortium promoting AI-driven computational structural biology. Japan-based only company participating in this global consortium alongside leading biotech companies and academic institutions.
  • Sakura Internet (さくらインターネット株式会社)coreStrategic or Co-development Partner · 30 September 2024Joint AI drug discovery research with Sakura Internet Research Institute. Co-authored NeurIPS 2024 paper on AVIDa-SARS-CoV-2 VHH dataset and antibody language models. Sakura Internet built AI models for antigen-antibody interaction prediction using COGNANO's labeled datasets. Long-term research collaboration since 2020.
  • Osaka University — Namba Laboratory (大阪大学 難波啓一特任教授)coreStrategic or Co-development Partner · 1 October 2021Cryo-electron microscopy analysis of antigen-antibody complexes for COGNANO's VHH antibodies (including SARS-CoV-2 and TNBC projects). Structural biology expertise supporting COGNANO's biomarker validation.
  • Kyoto University Faculty of Agriculture — Minami Laboratory (京都大学農学部 南直治郎教授)coreStrategic or Co-development Partner · 15 June 2021Joint research on alpaca breeding efficiency improvement and alpaca VHH antibody technology development. Long-standing partnership supporting COGNANO's core alpaca colony research capabilities.
  • Kyoto University School of Medicine — Takamori Laboratory (京都大学医学部 高折晃史教授)coreStrategic or Co-development Partner · 1 April 2020Long-standing research collaboration on SARS-CoV-2 VHH antibody development, HIV-1 antibody drug and CAR-T therapy development, and TNBC biomarker research. Kyoto University provides virus experiments and clinical expertise. COGNANO provides VHH antibody discovery platform.
  • Japan Agency for Medical Research and Development (国立研究開発法人 日本医療研究開発機構 / AMED)majorStrategic or Co-development PartnerCOGNANO participates in AMED-funded virus and infectious disease technology development programs as a research collaborator. Projects include SARS-CoV-2 treatment antibody development and HIV-1 antibody drug development.
  • UAB (Ukraine Association of Biobank)minorStrategic or Co-development PartnerCOGNANO is exploring biobank partnership with UAB to access diverse patient samples for biomarker validation. UAB relocated from Kharkiv to Graz, Austria during the Russia-Ukraine war, maintaining a centralized biobank.
  • Osaka University — Inoue Laboratory (大阪大学 井上豪教授)majorStrategic or Co-development PartnerScience advisor and participant in AMED-BINDS program. Provides expertise in X-ray crystallography, cryo-electron microscopy, and structural biology for COGNANO's biomarker validation research.
  • Tokyo University — Wada Laboratory (東京大学 和田教授)majorStrategic or Co-development PartnerCOGNANO collaborates with Tokyo University researchers on SARS-CoV-2 VHH antibody development. Provides virology expertise and experimental validation capabilities.
  • Cambridge Innovation Center (CIC)minorImplementation/ SI/ Consulting PartnerCOGNANO has been receiving mentorship from CIC Cambridge since November 2022. CIC introduced COGNANO to bio/tech mentors in Boston and facilitated connections with pharmaceutical companies and investors in the US biotech ecosystem.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

CogNano competitors and assessment

Company assessment

Broad incumbents

  • Recursion Pharmaceuticals: Recursion is a publicly-traded AI drug discovery company combining high-throughput biology, chemistry, and machine learning at scale. It is comparable to CogNano as a fellow AI-driven target and drug discovery platform, but operates at vastly larger scale with a broader pipeline and a different underlying data modality (high-throughput phenotypic screening vs. VHH antibody-based target discovery).
  • Insilico Medicine: Insilico Medicine is an AI-driven drug discovery company with end-to-end capabilities from target identification through clinical development. It is comparable to CogNano as a fellow AI-discovered target company pursuing novel disease biology (longevity, fibrosis, oncology), but is far more capitalized, employs a generative chemistry–centric approach, and competes for the same pharma partnership opportunities.
  • Isomorphic Labs: Isomorphic Labs is Alphabet's drug discovery company applying DeepMind's AI (AlphaFold) to pharma R&D. It is comparable to CogNano as an AI-driven drug discovery company, but operates at the hyperscaler level, focuses on structure prediction and chemistry, and competes for global pharma partnerships at a different scale.

Direct peers

  • AbCellera Biologics: AbCellera is a leading antibody discovery platform partnering with pharma to discover fully human therapeutic antibodies using single-cell screening and AI. It is the most directly comparable peer to CogNano in antibody discovery, though AbCellera focuses on human mAbs at massive scale and partnered economics (e.g., with Eli Lilly for COVID-19 antibodies) while CogNano focuses on alpaca VHHs with a data/AI-centric moat.
  • Adimab: Adimab is a privately-held antibody discovery and engineering company offering a yeast-based platform for therapeutic antibody leads. It is directly comparable to CogNano as an antibody platform business with pharma partnership economics, but focuses on human/yeast display antibodies rather than alpaca VHHs and offers engineering rather than target discovery as its core value.
  • BigHat Biosciences: BigHat Biosciences designs next-generation antibody therapeutics using a wet lab + ML platform for antibody engineering. It is a close peer to CogNano in combining biological antibody data with AI/ML to produce better therapeutic candidates, though focused on engineering existing antibodies rather than discovering novel disease targets.
  • NaturalAntibody: NaturalAntibody is a Poland-based antibody AI engineering service that partners with CogNano on antibody data processing workflows. It is a direct peer in the AI antibody space, offering data/AI tooling for antibody discovery and engineering with comparable scientific positioning but a service-model rather than proprietary animal-library business.

Emerging players

  • Generate Biomedicines: Generate Biomedicines is a Flagship Pioneering company using generative AI to design novel protein therapeutics including antibodies. It is comparable to CogNano as a generative biology company pursuing programmable biologics, but focuses on de novo protein generation rather than target discovery from VHH libraries and is far more capitalized.
  • Antiverse: Antiverse is a UK-based startup using AI/ML to design antibody therapeutics, including a platform for novel antigen discovery. It is comparable to CogNano as an AI-driven antibody discovery peer at a similar early stage, though focused on in silico antibody design against known targets rather than alpaca-library-driven novel target discovery.
  • Cradle Bio: Cradle is an Amsterdam-based AI protein design company focused on generative models for therapeutic and industrial proteins. It is comparable to CogNano as a generative biology peer operating in adjacent modalities, but focuses on general protein design rather than antibody target discovery and serves different downstream customers.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

CogNano social profiles

Digital presence

CogNano financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CogNano leadership team

Management profile

Number of profiles

Profiles13 records

CogNano subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

CogNano funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CogNano M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CogNano

What does CogNano do?

CogNano designs and produces VHH (single-domain) antibodies derived from its proprietary alpaca colonies and combines next-generation sequencing data with machine learning and large language models to discover disease-specific structural biomarkers and drug targets for pharmaceutical and diagnostic partners. The company licenses labeled VHH antigen-antibody datasets, provides research-use antibody samples under Material Transfer Agreements, and offers fee-for-service biomarker discovery engagements alongside drug target licensing to pharma and biotech clients.

Is CogNano a public or private company?

CogNano is a private company. It is classified as venture growth investor backed and is currently operating.

When was CogNano founded?

CogNano was founded in 2014. It employs 1 to 10 people.

Where is CogNano based?

CogNano is headquartered in Kyoto, Japan, in the Asia region.

How does CogNano make money?

Five revenue lines are on record. Research Use VHH Antibody Sample Provision is the primary driver. The others are data Licensing, biomarker Discovery Services, drug Target Licensing and daughter Venture Equity / Royalties.

Who are CogNano's main competitors?

Broad incumbents on record are Recursion Pharmaceuticals, Insilico Medicine and Isomorphic Labs. Direct peers are AbCellera Biologics, Adimab, BigHat Biosciences and NaturalAntibody. Emerging players are Generate Biomedicines, Antiverse and Cradle Bio.

Does CogNano have an API?

No public API is recorded for CogNano.

What industry is CogNano in?

CogNano's product category is Biotechnology / Antibody Drug Discovery. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals